Duvelisib: Additional Ph II DYNAMO data

Additional data from the open-label, international Phase II DYNAMO trial in 129 patients with follicular lymphoma (n=83), small lymphocytic lymphoma (SLL) (n=28) or marginal zone lymphoma (n=18) who are refractory to Rituxan rituximab and to either chemotherapy or radioimmunotherapy showed that twice-daily 25 mg oral duvelisib for up to thirteen 28-day cycles led to a median PFS of 8.4 months, median OS of 18.4 months and median duration of response of 9.9 months. Duvelisib was generally well tolerated. Data were presented at the American Society of Hematology meeting in San Diego. Infinity previously reported that duvelisib led to an ORR of 46%, all of which were partial responses (see BioCentury, June 20, 2016). Duvelisib is in the Phase III DUO trial to treat relapsed or refractory chronic lymphocytic leukemia (CLL)...